LENZ Therapeutics Inc

For the period ended Mar 31, 2025. Filed May 7, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 7, 2025

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except for shares and par value)

	March 31, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$23,042	$20,158
Marketable securities	170,934	188,872
Prepaid expenses and other current assets	3,769	2,773
Restricted cash	114	114
Total current assets	197,859	211,917
Property and equipment, net	926	651
Operating lease right-of-use asset	1,069	1,338
Other assets	1,398	1,398
Total assets	$201,252	$215,304
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$3,661	$4,257
Accrued liabilities	4,908	6,149
Total current liabilities	8,569	10,406
Operating lease liability, net	673	814
Total liabilities	9,242	11,220
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 27,543,120 and 27,531,490 shares issued at March 31, 2025 and December 31, 2024, respectively; and 27,535,663 and 27,518,439 shares outstanding at March 31, 2025 and December 31, 2024, respectively	1	1
Additional paid-in capital	351,519	348,901
Accumulated deficit	(159,633)	(145,014)
Accumulated other comprehensive income	123	196
Total stockholders’ equity	192,010	204,084
Total liabilities and stockholders’ equity	$201,252	$215,304

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.